ERAL1 and breast carcinoma: Thus a phytoestrogenic nutraceutical with the desirable estrogenic attributes displayed by SM6Met may alleviate menopausal symptoms through ERβ activation, whilst as a positive side effect it might prevent the development of breast cancer through ERα antagonism [42].